Preclinical Oncology Studies

Bridging the gap from bench to bedside.

Traditional preclinical pipelines can be slow, disjointed, and disconnected from clinical outcomes. At LIDE, we offer a translational-first roadmap: preclinical focus, clinical mindset. Our approach is built for efficiency, relevance, and scientific rigor. From patient-derived cells through in vivo validation, our integrated platforms streamline decision-making for more powerful downstream impact.

Our Proven Preclinical Workflow

1. CR Cells as the In Vitro Foundation

  • Use Conditionally Reprogrammed (CR) cells: high-fidelity, patient derived cell lines that preserve tumor heterogeneity.
  • Many matched to PDX models for further downstream studies.
  • Ideal for rapid screening, target validation, and generating organoid or CDX material.

2. Rapid Functional Translation

  • Shift from in vitro observations to in vivo relevance within 7 days using MiniPDX in-vivo 3D organoid assays.
  • Skip CDX models entirely and prioritize leveraging PDX models that are more translatable
  • Offers ~92% predictive correlation with clinical outcomes, validated across diverse indications.

3. Validate with PDX Platforms

  • Access the world’s second-largest biobank: 2,300+ low passage, clinically annotated PDX models across 50 cancer types.
  • Leverage hard-to-find models with rare mutations, resistance phenotypes, or detailed treatment histories.

4. Inform Trials with Fresh Patient Samples

  • Get ahead of recruitment strategies by leveraging LIDE’s fresh patient sample network for biomarker discovery and stratification studies.
  • LIDE’s K-Cell Omics analysis can work with even small volumes of patient sample